hC Bioscience

Cambridge, MA · Founded 2021 · CIK 0001898412 · Biotech

hcbioscience.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$12M
1 Form D · Dec 2021
58 months since last filing
Contracts
—
No federal contracts on record
Patents
13
0 granted · 13 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$11,999,999
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2085Medium Corp—$31M
2086FORGE THERAPEUTICS INC——
2087CryptoMedix, Inc.—$100K
2088hC Bioscience—$12M
2089Eden Food International Inc.—$13M
2090General Translation, Inc.—$2.4M
2091CNS Pharmaceuticals, Inc.—$23M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Christopher AhernExecutive Officer
  • Benjamin ChenDirector
  • Steven GillisDirector
  • Sacha MannDirector
  • Brad MargusDirector
  • Seiji MiyaharaDirector
  • David MoskowitzDirector
  • Leslie WilliamsDirector · Executive Officer

Patents

USPTO · 0 granted of 13
  • Universal Suppressor Trnas And Uses Thereofapplication
  • Modified Transfer Rna With Improved Activityapplication
  • Trna Therapeutics For Hemophiliaapplication
  • Trna Therapeutics For Hemophiliaapplication
  • Minimally-sized Dna Threads For Trna Therapyapplication
  • Trna Therapeutics For Hemophiliaapplication
  • Trna Therapeutics For Hemophiliaapplication
  • Dna Microthreads For Trna Therapyapplication
  • Universal Suppressor Trnas And Uses Thereofapplication
  • Modified Transfer Rna With Improved Activityapplication
  • Trna Therapeutics For Hemophiliaapplication
  • MODIFIED tRNA WITH IMPROVED EFFECTS – BACKBONE MODIFICATIONSapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.